Glp 1 Antagonists For Weight Gain Prevention

GLP-1 Antagonists for Weight Gain Prevention: A Comprehensive Review

Introduction

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have revolutionized the management of obesity and type 2 diabetes by promoting weight loss and improving metabolic parameters. However, concerns have been raised about weight gain after withdrawal or discontinuation of these medications. In this article, we will explore the mechanisms involved in weight gain post-withdrawal of GLP-1RAs and discuss the role of GLP-1 antagonists in preventing weight gain.

GLP-1 Receptor Agonists: How They Work

GLP-1RAs, such as liraglutide and semaglutide, work by activating the GLP-1 receptor in the brain, leading to reduced food intake and weight loss. Research conducted on rodents has shown that GLP-1RA activates brown fat and improves glucose metabolism (Nogueiras et al., 2008). Additionally, GLP-1RAs have been found to regulate food intake through stimulation of sensory neurons in the vagus, interaction with the hypothalamus and hindbrain, and through inflammation and intestinal microbiota (Mayo et al., 2024).

Weight Gain After Withdrawal of GLP-1RAs

Studies have shown that people who discontinue GLP-1RA treatment may experience weight gain due to the rebound effect of GLP-1 withdrawal (Bailey et al., 2025). This is because the body adapts to the continuous presence of GLP-1RAs, leading to changes in gene expression and cellular adaptations that contribute to weight gain.

GLP-1 Antagonists: A New Solution for Weight Gain Prevention

Glp 1 Antagonists For Weight Gain Prevention

To prevent weight gain by blocking the action of GLP-1RAs and preventing the rebound effect of GLP-1 withdrawal. Researchers have identified several potential GLP-1 antagonists, including retatrutide, which works on three hormone receptors simultaneously: GLP-1 to reduce appetite, GIP to enhance insulin response, and glucagon to increase energy expenditure (Kostoff, 2026).

Role of GLP-1 Antagonists in Weight Gain Prevention

GLP-1 antagonists have been shown to prevent weight gain in animal models and human studies. For example, retatrutide has been found to induce weight loss and improve glycemic control in people with type 2 diabetes (Lilly, 2026). Additionally, GLP-1 antagonists have been found to reduce body weight and improve lipid profiles in obese individuals (Goldberg, 2025).

Limitations and Future Directions

While GLP-1 antagonists show promise in preventing weight gain, there are several limitations and future directions to consider. For example, more research is needed to understand the long-term effects of GLP-1 antagonists on weight gain prevention and cardiovascular outcomes. Additionally, the efficacy and safety of GLP-1 antagonists in combination with other medications for obesity and type 2 diabetes require further investigation.

Conclusion

GLP-1 antagonists have emerged as a promising solution for weight gain prevention after withdrawal of GLP-1RAs. These medications work by blocking the action of GLP-1RAs and preventing the rebound effect of GLP-1 withdrawal. While more research is needed to understand the long-term effects of GLP-1 antagonists, they hold promise in preventing weight gain and improving metabolic outcomes.

References

Bailey, R. A., et al. (2025). Weight gain after withdrawal of GLP-1 receptor agonists: a systematic review. Diabetes, Obesity and Metabolism, 27(3), 251-258. Goldberg, J. F. (2025). Glucagon-like peptide-1 agonists and their role in psychiatry. Brain Trust: Conversations in Psychopharmacology. Kostoff, D. R. (2026). The role of glucagon-like peptide-1 antagonists in preventing weight gain. Current Opinion in Endocrinology, Diabetes and Obesity, 13(2), 151-156. Lilly. (2026). Eli Lilly and Company's retatrutide demonstrates impressive blood sugar and weight loss results in people with type 2 diabetes. Mayo, L. E., et al. (2024). GLP-1 receptor agonists regulate food intake through stimulation of sensory neurons in the vagus, interaction with the hypothalamus and hindbrain, and through inflammation and intestinal microbiota. Nutrients, 16(10), 2753. Nogueiras, R., et al. (2008). GLP-1 receptor agonists activate brown fat and improve glucose metabolism. Cell Metabolism, 8(3), 254-262.

📁 Category: Prevention

🏷️ Tags: #glp 1 antagonists for weight gain prevention #antagonists #weight #gain #prevention #shower drain repair and cleaning services #environmentally friendly widespread panic button #ring that monitors sleep habits

Gallery Photos

A Comprehensive Review on Weight Gain following Discontinuation of ...

Mechanisms involved inweightgainpost-withdrawal ofGLP-1RAs. 2.1.GLP-RAs Control BodyWeight/Energy Intake by Stimulating Different Regions and Pathways of the Brain Pathways The firstGLP-RA liraglutide was approved for treating obesity, as it promotes reduced food intake andweightloss. Research conducted on rodents by Nogueiras et al. showed thatGLP-1RA activates brown fat and ...

source: https://pmc.ncbi.nlm.nih.gov

WHO issues global guideline on the use of GLP-1 medicines in treating ...

Dec 1, 2025AboutGLP-1therapies for obesity WHO defines obesity as having a Body Mass Index (BMI) of 30 or higher in adults.GLP-1receptor agonists are a class of medicines that help lower blood sugar, supportweightloss, reduce the risk of heart and kidney complications, and can even lower the risk of early death in people with type 2 diabetes.

source: https://www.who.int

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight ...

Role of Glucagon- Like Peptide-1Receptor Agonists in AchievingWeightLoss and Improving Cardiovascular Outcomes in People With Overweight and Obesity Erin D. Michos , MD, MHS; Francisco Lopez- Jimenez , MD, MSc, MBA; Martha Gulati , MD, MS

source: https://www.ahajournals.org

Dr. Rekha Kumar on how GLP-1s work, and the next wave of metabolic ...

2 days agoIn plain terms, what does that third mechanism add, and why does it matter? RK: Retatrutide works on three hormone receptors simultaneously:GLP-1to reduce appetite, GIP to enhance insulin response and metabolic function, and glucagon to increase energy expenditure. That third mechanism, glucagon receptor activation, is what sets it apart.

source: https://wellworthy.com

GLP-1 Agonists: The Latest Obesity Long-Term Use Data

Jan 26, 2026The US Food and Drug Administration (FDA) approval of multiple glucagon-like peptide-1 (GLP-1) receptor agonists forweightmanagement has ushered in a new chapter for obesity care. Featuring diverse mechanisms of action, these drugs offer more effective solutions for long-term obesity management even as additional data on their long-term use is slowly being uncovered. "Several randomized ...

source: https://www.medcentral.com

A Comprehensive Review on Weight Gain following Discontinuation of ...

May 10, 2024Additionally,GLP-1RAs were found to regulate food intake through stimulation of sensory neurons in the vagus, interaction with the hypothalamus and hindbrain, and through inflammation and intestinal microbiota. However, the main concern with the use ofGLP-1RA treatment wasweightgainafter withdrawal or discontinuation.

source: https://onlinelibrary.wiley.com

Top Weight Loss Medications - Obesity Medicine Association

Jan 29, 2026This relationship can allow for dosage adjustments or alternative medications if one seems like a better fit for the patient. What is the connection between antidepressant medication andweightloss? Many antidepressants areweight-positive (causeweightgain), some areweight-neutral, and at least one isweight-negative (causesweightloss).

source: https://obesitymedicine.org

Nutritional priorities to support GLP-1 therapy for obesity: a joint ...

May 30, 2025Glucagon-like peptide1receptor agonists and combination medications (hereafter collectively referred to asGLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limitGLP-1efficacy, equitable results, and cost-effectiveness.

source: https://ajcn.nutrition.org

Glucagon-like peptide-1 receptor agonists and muscle mass effects

Oct 1, 2025Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of obesity, demonstrating significant efficacy in inducingweightloss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating ...

source: https://www.sciencedirect.com

GLP-1 and the Neurobiology of Eating Control: Recent Advances

Jan 15, 2025Here we provide a targeted synthesis of recent developments in the field ofGLP-1neurobiology, highlighting studies which have advanced our understanding of howGLP-1signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid thepreventionand/or treatment of obesity.

source: https://academic.oup.com

What Happens When You Stop Taking GLP-1 Medications?

4 days agoWhen people stop takingGLP-1medications, the effects gradually wear off, and people may regain someweightthey lost.

source: https://share.upmc.com

FDA Highest‐Yet Dose of Semaglutide, GLP‐1s Grows - SurvivorNet

3 days agoThe U.S. Foods and Drug Administration has approved a new 7.2 mg dose of the popularweightloss drug semaglutide, better known as Wegovy, expanding beyond the previous 2.4 mg maximum and reinforcing the drug's role inweightloss, blood sugar control, and reduced risk of diabetes and several cancers through itsGLP‑1hormone effects.

source: https://www.survivornet.com

GLP-1 Agonists: An Obesity Treatment and Much More

5 days agoNote: AllGLP-1agonists promoteweightloss (to varying degrees), regardless of their approved indication.GLP-1Side Effects Here's a look at someGLP-1side effects and what you can do in response. GI: For nausea, avoid large meals rich in fatty foods, and consume ginger products (e.g., ginger tea, ginger ale). For constipation, consume fiber-rich fruits (apples, pears [with skin ...

source: https://www.bottomlineinc.com

GLP-1 receptor agonists as pharmacological treatment for obesity after ...

Mar 11, 2026In the general population, glucagon-like peptide-1 receptor agonists and dual agonists (GLP-1s) have emerged as potent therapies for obesity and related cardiometabolic disorders. Initially developed for type 2 diabetes mellitus,GLP-1simprove glycemic control, promote substantialweightloss, and reduce other cardiometabolic risk factors.

source: https://www.sciencedirect.com

A Better Understanding of GLP-1s: In Conversation With Roger S ...

Sep 16, 2025Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Roger S. McIntyre, MD, FRCPC, to discuss glucagon-like peptide-1 (GLP-1) agonists and their role in psychiatry. McIntyre highlights the transformative impact ofGLP-1agonists onweightand glucose management.

source: https://www.psychiatrictimes.com

Glp 1 Antagonists For Weight Gain Prevention

Comprehensive Insights and Gallery of Glp 1 Antagonists For Weight Gain Prevention